231 related articles for article (PubMed ID: 10559017)
1. Severe hyperlipidemia in apolipoprotein E2 homozygotes due to a combined effect of hyperinsulinemia and an SstI polymorphism.
Sijbrands EJ; Hoffer MJ; Meinders AE; Havekes LM; Frants RR; Smelt AH; De Knijff P
Arterioscler Thromb Vasc Biol; 1999 Nov; 19(11):2722-9. PubMed ID: 10559017
[TBL] [Abstract][Full Text] [Related]
2. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia.
de Beer F; Stalenhoef AF; Hoogerbrugge N; Kastelein JJ; Gevers Leuven JA; van Duijn CM; Havekes LM; Smelt AH
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):294-9. PubMed ID: 11834531
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of the APOA1 XmnI and APOC3 SstI polymorphisms in the APOA1/C3/A4 gene cluster and risk of incident myocardial infarction in men.
Liu S; Song Y; Hu FB; Niu T; Ma J; Gaziano M; Stampfer MJ
Atherosclerosis; 2004 Nov; 177(1):119-26. PubMed ID: 15488874
[TBL] [Abstract][Full Text] [Related]
4. Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects.
Marcil M; Boucher B; Gagné E; Davignon J; Hayden M; Genest J
J Lipid Res; 1996 Feb; 37(2):309-19. PubMed ID: 9026529
[TBL] [Abstract][Full Text] [Related]
5. Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia.
Groenendijk M; Cantor RM; Blom NH; Rotter JI; de Bruin TW; Dallinga-Thie GM
J Lipid Res; 1999 Jun; 40(6):1036-44. PubMed ID: 10357835
[TBL] [Abstract][Full Text] [Related]
6. Influence of polymorphism (RFLP-sstI) at the apolipoprotein C-III gene locus on the lipoprotein metabolism and insulin resistance in essential hypertensive patients. Interaction between gender and genetic polymorphism.
Espino-Montoro A; Barrios-Artillo M; López-Chozas JM; Cayuela A; Stiefel P; Villar J
Nutr Metab Cardiovasc Dis; 2003 Aug; 13(4):194-201. PubMed ID: 14650351
[TBL] [Abstract][Full Text] [Related]
7. Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects.
Ooi EM; Janus ED; Grant SJ; Sinclair LM; R Barrett PH
J Lipid Res; 2010 Aug; 51(8):2413-21. PubMed ID: 20413671
[TBL] [Abstract][Full Text] [Related]
8. The expression of type III hyperlipoproteinemia: involvement of lipolysis genes.
Henneman P; van der Sman-de Beer F; Moghaddam PH; Huijts P; Stalenhoef AF; Kastelein JJ; van Duijn CM; Havekes LM; Frants RR; van Dijk KW; Smelt AH
Eur J Hum Genet; 2009 May; 17(5):620-8. PubMed ID: 19034316
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
März W; Hoffmann MM; Scharnagl H; Fisher E; Chen M; Nauck M; Feussner G; Wieland H
J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
[TBL] [Abstract][Full Text] [Related]
10. Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2.
Huang Y; Schwendner SW; Rall SC; Mahley RW
J Biol Chem; 1996 Nov; 271(46):29146-51. PubMed ID: 8910571
[TBL] [Abstract][Full Text] [Related]
11. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia.
Mar R; Pajukanta P; Allayee H; Groenendijk M; Dallinga-Thie G; Krauss RM; Sinsheimer JS; Cantor RM; de Bruin TW; Lusis AJ
Circ Res; 2004 Apr; 94(7):993-9. PubMed ID: 15001527
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia.
Evans D; Seedorf U; Beil FU
Clin Genet; 2005 Oct; 68(4):369-72. PubMed ID: 16143024
[TBL] [Abstract][Full Text] [Related]
13. A high-carbohydrate diet enhances the adverse effect of the S2 allele of APOC3 SstI polymorphism on the TG/HDL-C ratio only in young Chinese females.
Song YY; Gong RR; Zhang Z; Li YH; Xiao LY; Zhou XD; Fang DZ
Braz J Med Biol Res; 2011 Jun; 44(6):524-30. PubMed ID: 21603779
[TBL] [Abstract][Full Text] [Related]
14. Genetic determination of plasma lipids and insulin in the Czech population.
Hubacek JA; Waterworth DM; Poledne R; Pitha J; Skodová Z; Humphries SE; Talmud PJ
Clin Biochem; 2001 Mar; 34(2):113-8. PubMed ID: 11311220
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
[TBL] [Abstract][Full Text] [Related]
16. Expression of type III hyperlipoproteinemia in patients homozygous for apolipoprotein E-2 is modulated by lipoprotein lipase and postprandial hyperinsulinemia.
Brümmer D; Evans D; Berg D; Greten H; Beisiegel U; Mann WA
J Mol Med (Berl); 1998 Apr; 76(5):355-64. PubMed ID: 9587070
[TBL] [Abstract][Full Text] [Related]
17. Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291-->Ser mutation in the human LPL gene.
Zhang H; Reymer PW; Liu MS; Forsythe IJ; Groenemeyer BE; Frohlich J; Brunzell JD; Kastelein JJ; Hayden MR; Ma Y
Arterioscler Thromb Vasc Biol; 1995 Oct; 15(10):1695-703. PubMed ID: 7583546
[TBL] [Abstract][Full Text] [Related]
18. The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance.
de Villiers WJ; van der Westhuyzen DR; Coetzee GA; Henderson HE; Marais AD
Arterioscler Thromb Vasc Biol; 1997 May; 17(5):865-72. PubMed ID: 9157949
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III.
Dallinga-Thie GM; Bu XD; van Linde-Sibenius Trip M; Rotter JI; Lusis AJ; de Bruin TW
J Lipid Res; 1996 Jan; 37(1):136-47. PubMed ID: 8820109
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E2 transgenic rabbits. Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis.
Huang Y; Schwendner SW; Rall SC; Sanan DA; Mahley RW
J Biol Chem; 1997 Sep; 272(36):22685-94. PubMed ID: 9312550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
